Marine Lipopolysaccharide-based Vaccine Development Service

Marine Lipopolysaccharide-based Vaccine Development Service at CD BioGlyco

Marine lipopolysaccharide (LPS) has specific biological activities. For example, it is involved in bacterial survival in many hosts, has antigenic properties, as well as being involved in serological specificity, etc. Therefore, the development of vaccines centered on marine LPS with properties that attenuate bacterial virulence or increase the body's immunity is promising for research. At CD BioGlyco, we propose a comprehensive marine LPS vaccine development service in the context of Developing Marine Carbohydrate Vaccines.

Preparation of Marine LPS as Immunogens

First, we dissolve marine LPS in an organic solvent, and after a period of agitation and several dialysis, the solution is centrifuged. Then, the supernatant is freeze-dried to obtain the desired LPS immunogen. In addition, we use a gel chromatography column for further purification.

Coupling and Analysis of Marine LPS

First, we react to the terminal residues of marine LPS with differently designed bifunctional linkers. Then, they are reacted with residues of carrier proteins to form marine LPS-linker-protein couplers. In this method, we also utilize a site-selective modification approach to ensure that the couplers have the most binding sites.

In addition, we offer analysis of coupling compounds:

• Separation and purification of the coupling compounds using size exclusion chromatography columns.
• Analysis of the shape and mass-to-charge ratio of the couplers using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
• The molecular weights of the couplers are analyzed using fast-performance liquid chromatography (FPLC).
• The content of polysaccharides and proteins of the couplers is determined by the bicinchoninic acid method (BCA).

Preparation of the Vaccine

We prepare the vaccine by mixing immunogenic marine LPS coupling with stabilizers, emulsifiers, and adjuvants. Next, we provide mice immunization assays to analyze the ability of the vaccine to induce antibodies. We also provide enzyme-linked immunosorbent assay (ELISA) to analyze the effectiveness of the vaccine.

Fig.1 Marine LPS-based vaccine development services. (CD BioGlyco)

Publication

Technology: Decarboxylation amidation, SDS-PAGE, ELISA, Immunoassay

Journal: Journal of Biomedical Science

IF: 11.0

Published: 2020

Results: The authors characterized the synthesized coupled vaccine using SDS-PAGE and FPLC. Their polysaccharide and protein contents were also determined. ELISA showed that when mice were immunized with a 2.5 μg dose of lipid-A free lipopolysaccharide (LFPS) conjugate vaccine, serum immunoglobulin G against S. Typhimurium LPS was elicited. In addition, the straight-chain amide linker in the conjugate did not interfere with the desired immune response. Second, vaccines derived from unisolated LFPS or high-quality fractions showed the same effect in inducing serum immunoglobulin G antibodies. Evaluation of the efficacy of the vaccine indicated that when S. Typhimurium flagellin (FliC) was used as the adjuvant protein carrier, the vaccine was 74% effective and the survival rate of the mice was 80% on day 28 after tapping.

Fig.2 Design of polysaccharide–protein vaccine. (Chiu, et al., 2020)

Applications

• The development of marine LPS vaccines can be used to delve deeper into the biological functions of marine carbohydrates.
• Marine LPS has a strong influence on the survival of bacteria. Therefore, the development of marine LPS vaccines can help in the research of antibacterial vaccines.
• The development of marine LPS vaccines helps researchers study the effects of marine lipopolysaccharides on the organism's immune system.

Advantages

• We have professional after-sales service and provide complete product quality inspection reports.
• We have a high-quality compound screening technology platform combined with a wide range of compound libraries to provide one-stop vaccine development services to our global scientific clients.
• Our R&D team provides custom R&D services according to client's research needs.
• Our industry-leading vaccine development technology ensures that we provide our clients with high-quality, high-performance vaccine products.

CD BioGlyco specializes in biologically active compounds and offers a wide range of services in glycobiology to clients all over the world. We ensure the quality of every product our clients receive and provide detailed report interpretation. Please feel free to contact us for more information on the vaccine development of marine carbohydrates.